- Home
- EPSM vs AEON Comparison
EPSM vs AEON Comparison
Compare EPSM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | AEON |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EPSM | AEON |
|---|---|---|
| Price | $0.83 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 23.8K | ★ 796.5K |
| Earning Date | 11-24-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.18 |
| 52 Week High | $10.19 | $1.45 |
Technical Indicators
Market Signals| Indicator | EPSM | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 50.15 |
| Support Level | $0.83 | $0.23 |
| Resistance Level | $1.64 | $0.33 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 32.76 | 45.78 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.